ボナンザカジノ

Toggle navigation 日本語 English HomeAccess Development of a new control method for viral infection. Development of a new control method for viral infection. Development of a new control method for viral infection. Development of a new control method for viral infection. 1th floorDiv. of HTLV-1/ATL Carcinogenesis Therapeutics Our research is aimed at elucidating the mechanism of adult T-cell leukemia/lymphoma development at the molecular and individual levels and developing new preventive and therapeutic methods. 2nd floorDiv. of Neuroimmunology Our mission is to elucidate the pathogenesis of HAM/TSP, an inflammatory neurological disease in the spinal cord caused by HTLV-1 infection, and to develop new therapeutic strategies. 3rd floorDiv. of Biological information Technology The mission of our team is to develop the new antivirals by the artificial noninfectious virus, replicon, assay system. The research for HCV, HBV, Flu, and human coronaviruses including SARS-CoV-2, is within our scope. 4th floorDiv. of Antiviral Therapy The mission of our research group is to develop new therapeutics against certain refractory viral infections such as HIV and HBV. We also aim to establish novel strategies to combat with emerging diseases including COVID-19. 1th floorDiv. of Translational Medicine Our mission is to put new medical seeds born from the results of basic research in various fields into practical use as pharmaceuticals and medical technology. It aims at a smooth transition from the basic research stage to clinical application by continuously capturing non-clinical research to clinical development. Copyright (C) Joint Research Center for Human Retrovirus Infection Kagoshima University Campus All Rights Reserved. Back to Top